Caisse de depot et placement du Quebec Invests $154.30 Million in United Therapeutics Corporation $UTHR

Caisse de depot et placement du Quebec bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 284,783 shares of the biotechnology company’s stock, valued at approximately $154,304,000. Caisse de depot et placement du Quebec owned about 0.66% of United Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Gallagher Fiduciary Advisors LLC purchased a new stake in United Therapeutics in the second quarter valued at approximately $307,000. Odyssean LLC boosted its position in shares of United Therapeutics by 76.4% during the second quarter. Odyssean LLC now owns 5,445 shares of the biotechnology company’s stock worth $2,950,000 after buying an additional 2,358 shares during the period. Man Group plc acquired a new stake in shares of United Therapeutics in the second quarter valued at $73,087,000. Roberts Glore & Co. Inc. IL acquired a new position in United Therapeutics during the 2nd quarter worth about $244,000. Finally, Jupiter Topco LLC acquired a new position in United Therapeutics during the 2nd quarter worth about $450,140,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on UTHR shares. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. increased their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Bank of America dropped their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Royal Bank Of Canada cut their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Finally, Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a report on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

Insider Buying and Selling

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $511.97, for a total value of $4,863,715.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $166,105,082.71. This trade represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $23,631,280.08. This trade represents a 15.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 424,075 shares of company stock worth $227,683,710. Insiders own 8.60% of the company’s stock.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $516.68 on Thursday. The company has a market cap of $22.16 billion, a price-to-earnings ratio of 18.49, a price-to-earnings-growth ratio of 1.76 and a beta of 0.59. The stock’s 50-day moving average is $531.06 and its two-hundred day moving average is $538.56. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same period in the previous year, the company posted $6.41 earnings per share. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. Equities research analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.